Please login to the form below

Not currently logged in
Email:
Password:

Celsentri launched in the UK

Pfizer's drug Celsentri, the first new oral class of HIV treatment for more than ten years, has been launched in the UK yesterday (November 19).

Pfizer's drug Celsentri (maraviroc), the first new oral class of HIV treatment for more than ten years, has been launched in the UK yesterday (November 19).

Celsentri is now available to treatment experienced patients infected with only CCR5-tropic HIV-1 in combination with other antiretroviral medicinal products in the UK.

Celsentri's is a first in a new class of CCR5 antagonists, and its novel mode of action prevents the HIV virus manufactured infected cells from entering uninfected cells by blocking the CCR5 co-receptor entry route on the cell wall.

Patients will submit to a diagnostic test to verify they have the type of HIV virus treatable with the drug. However, Celsentri could be used for treatment naîve patients and Pfizer is currently studying this possibility in an ongoing study called MERIT.

Celsentri was authorised by the EMEA in September 2007.

A Datamonitor report published in April 2007 projects Celsentri's sales to reach USD 350m in 2015, while the total value of the HIV market could grow to USD 10.6bn in 2015. The HIV market was worth USD 7.1bn in 2005.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics